Screener
Chemed CHE Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $40.22M-83.9% | $16.86M-90.3% | $74.52M-58.2% | $129.75M-45.6% | $249.9M+12.1% | ||
| $6.72M-96.4% | $215.48M-24.6% | $182.58M+6.7% | $215.57M+9.7% | $184.88M0.0% | ||
| $248K-97.3% | $7.21M-7.5% | $7.54M-7.9% | $8.24M-16.8% | $9.15M-14.8% | ||
| $291.24M-40.7% | $274.06M-45.4% | $302.62M-23.3% | $395.24M-19.4% | $491.38M+5.8% | ||
| $208.5M+3.1% | $207.73M+4.0% | $205.66M+2.4% | $203.94M+1.5% | $202.28M0.0% | ||
| $699.4M+4.9% | $687.5M+3.1% | $667M0.0% | $666.99M0.0% | $667M+0.7% | ||
| $78.6M-10.0% | $80.42M-10.6% | $82.76M+260% | $84.93M-10.4% | $87.36M-10.0% | ||
| $1.58B-8.0% | $1.54B-11.0% | $1.54B-7.8% | $1.62B-8.2% | $1.72B-1.0% | ||
| $84.71M+66.5% | $65.7M+37.8% | $64.46M+46.0% | $48.1M+7.0% | $50.86M+18.3% | ||
| $319.85M+21.2% | $321.42M+10.6% | $287.13M+0.5% | $292.04M+10.3% | $263.89M+0.8% | ||
| $140M— | $91.2M— | —— | —— | —— | ||
| $749.08M+44.2% | $687.82M+26.3% | $558.78M+1.7% | $546.94M+2.5% | $519.36M-1.6% | ||
| $37.61M-53.0% | $80M0.0% | $80M0.0% | $80M0.0% | $80M0.0% | ||
| $3.07B+8.5% | $3.01B+8.2% | $2.96B+8.6% | $2.89B+9.4% | $2.83B+10.1% | ||
| $830.51M-30.7% | $847.99M-28.2% | $979.41M-12.5% | $1.08B-12.9% | $1.2B-0.7% | ||
| $1.58B-8.0% | $1.54B-11.0% | $1.54B-7.8% | $1.62B-8.2% | $1.72B-1.0% |
FAQ
- What are Chemed's total assets?
- Chemed (CHE) holds $1.6B in total assets, down 8.1% year over year.
- How much debt does Chemed have?
- Chemed carries $181.3M in total debt against $830.5M of shareholders' equity, a debt-to-equity ratio of 0.22.
- How much cash does Chemed have?
- Chemed holds $40.2M in cash and equivalents.
- Can Chemed cover its short-term obligations?
- Its current ratio is 0.91 — current liabilities exceed current assets.
- Where does Chemed's balance sheet data come from?
- Every line is extracted from Chemed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
